Home > Aminopeptidase & > Ubenimex

Ubenimex

乌苯美司,贝他定,Bestatin

Ubenimex (Bestatin)是一种竞争性氨肽酶B抑制剂，作用于K562细胞，IC50为100 mg/ml。

目录号
EY1237
EY1237
EY1237
EY1237
纯度
99.39%
99.39%
99.39%
99.39%
规格
1 mg
5 mg
25 mg
50 mg
原价
180
400
1000
1800
售价
180
400
1000
1800
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Ubenimex, also known as bestatin, is a competitive protease inhibitor.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Sekine K, et al. Leukemia, 1999, 13(5), 729-734.
    [2] Inoue, T., et al. 1994. J. Clin. Endocrinol. Metab. 79: 171-175.
    [3] Lkhagvaa, B., et al. 2008. Cytokine. 44: 386-391.
    [4] Jia, M.R., et al. 2010. Front Neurosci. 4: 50.

    分子式
    C16H24N2O4    		 分子量
    308.37    		 CAS号
    58970-76-6    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    2 mg/mL     		Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02086487 Myeloid Leukemia, Chronic Drug: Nilotinib 300 mg. King Abdullah International Medical Research Center|Novartis Phase 4 2013-03-01 2017-03-06
    NCT02954978 Parkinson Disease|Parkinsons Disease With Dementia Drug: Placebo Oral Capsule|Drug: Nilotinib 150mg oral capsule [Tasigna]|Drug: Nilotinib 300mg oral capsule [Tasigna] Georgetown University Phase 2 2017-01-01 2017-03-15
    NCT01562847 Chronic Myeloid Leukemia Drug: Nilotinib Seoul St. Mary's Hospital|Novartis Phase 2 2011-07-01 2014-01-10
    NCT00980018 Chronic Myelogenous Leukemia Drug: Nilotinib Novartis Pharmaceuticals|Novartis Phase 4 2009-12-01 2015-04-14
    NCT01316250 Chronic Myelogenous Leukemia Drug: Nilotinib American University of Beirut Medical Center 2010-08-01 2016-07-23
    NCT01698905 Chronic Myeloid Leukemia Drug: nilotinib Novartis Pharmaceuticals|Novartis Phase 2 2012-12-01 2016-11-27
    NCT00976612 Gastrointestinal Stromal Tumors Drug: Nilotinib Asan Medical Center 2009-01-01 2013-07-03
    NCT01856283 Leukemia, Myeloid, Chronic-Phase Drug: Nilotinib 300mg BID Niguarda Hospital Phase 2 2013-03-01 2016-09-20
    NCT01131325 CML|Philadelphia Chromosome Positive (Ph+)|Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels Drug: nilotinib Novartis Pharmaceuticals|Novartis Phase 4 2010-10-01 2015-10-06
    NCT01810718 Chronic Graft Versus Host Disease Drug: nilotinib Gruppo Italiano Trapianto di Midollo Osseo Phase 1 2011-11-01 2016-07-05
    NCT01690065 Chronic Myeloid Leukemia in Myeloid Blast Crisis|Untreated Adult Acute Myeloid Leukemia Drug: Nilotinib+AD induction Ulsan University Hospital|The Korean Society of Hematology CML working party Phase 2 2012-09-01 2016-05-10
    NCT02947893 Alzheimer's Disease Drug: Placebo Capsule(s) Once a Day by Mouth|Drug: Nilotinib Capsule(s) Once a Day by Mouth Georgetown University Phase 2 2017-01-01 2017-01-17
    NCT01395121 Mucosal Lentiginous Melanoma|Acral Lentiginous Malignant Melanoma Drug: nilotinib Institute of Cancer Research, United Kingdom|Royal Marsden NHS Foundation Trust Phase 2 2009-12-01 2012-05-18
    NCT00788775 Mucosal Lentiginous Melanoma|Acral Melanoma|Melanoma Drug: Nilotinib Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Novartis Phase 2 2009-01-01 2016-10-16
    NCT01089595 GIST|Metastatic Disease Drug: Nilotinib|Drug: Nilotinib with Imatinib Fox Chase Cancer Center|Novartis Phase 2 2009-02-01 2017-01-25
    NCT02587169 Retroperitoneal Liposarcoma|Retroperitoneal Leiomyosarcoma|Chondrosarcoma Drug: Nilotinib-adriamycin Broto, Javier Mart铆n, M.D. Phase 1|Phase 2 2012-01-01 2015-10-23
    NCT01270893 Gastrointestinal Cancer Drug: Nilotinib M.D. Anderson Cancer Center|Novartis Phase 2 2011-01-01 2012-08-01
    NCT01222143 Acute Myeloid Leukemia Drug: NOVE-HiDAC|Drug: Nilotinib University Health Network, Toronto|Novartis Pharmaceuticals Phase 1|Phase 2 2010-10-01 2015-06-19
    NCT02108951 Philidelphia Positive Chronic Myeloid Leukaemia Drug: Nilotinib Novartis Pharmaceuticals|Novartis Phase 3 2014-07-01 2016-07-26
    NCT01207492 Pigmented Villonodular Synovitis|Diffuse-type Giant Cell Tumor|Tenosynovial Giant Cell Tumor Drug: nilotinib Andrew J. Wagner, MD, PhD|Brigham and Women's Hospital|Massachusetts General Hospital|Novartis|Dana-Farber Cancer Institute Phase 2 2010-09-01 2016-10-03
    NCT01528085 Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia Drug: Nilotinib Johann Wolfgang Goethe University Hospital Phase 2 2012-01-01 2015-09-29
    NCT02379416 Solid Tumors Drug: Nilotinib + Paclitaxel National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 1 2015-02-20 2017-02-03

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：